Parnell Pharmaceuticals (OTCMKTS:PARNF – Get Free Report) and Canopy Growth (NASDAQ:CGC – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.
Profitability
This table compares Parnell Pharmaceuticals and Canopy Growth’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Parnell Pharmaceuticals | N/A | N/A | N/A |
| Canopy Growth | -65.33% | -21.91% | -14.34% |
Institutional and Insider Ownership
3.3% of Canopy Growth shares are owned by institutional investors. 0.4% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Parnell Pharmaceuticals | N/A | N/A | N/A | N/A | N/A |
| Canopy Growth | $293.63 million | 1.47 | -$190.29 million | ($0.45) | -2.14 |
Parnell Pharmaceuticals has higher earnings, but lower revenue than Canopy Growth.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Parnell Pharmaceuticals and Canopy Growth, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Parnell Pharmaceuticals | 0 | 0 | 0 | 0 | 0.00 |
| Canopy Growth | 1 | 2 | 2 | 0 | 2.20 |
Summary
Canopy Growth beats Parnell Pharmaceuticals on 5 of the 8 factors compared between the two stocks.
About Parnell Pharmaceuticals
Parnell Pharmaceuticals Holdings Ltd, a commercial-stage pharmaceutical company, focuses on developing, manufacturing, and marketing animal pharmaceutical products worldwide. The company operates through four segments: Companion Animal, Production Animal – U.S., Production Animal – Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproductive hormone products for enhancing cattle breeding performance; Zydax for the treatment of osteoarthritis (OA) in dogs and horses; and Glyde, a nutraceutical product for the treatment of OA, as well as Parnell PROcept, which adds an additional injection of estroPLAN after the first injection. The company also offers mySYNCH, a digital tool to help veterinarians and producers optimize reproduction and maximize economic gains. Parnell Pharmaceuticals Holdings Ltd was incorporated in 2009 and is headquartered in Alexandria, Australia.
About Canopy Growth
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.
Receive News & Ratings for Parnell Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parnell Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
